Literature DB >> 5112211

Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia.

H L Klawans, R R McKendall.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5112211     DOI: 10.1016/0022-510x(71)90087-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  8 in total

Review 1.  [Antipsychotic-induced tardive syndromes].

Authors:  W Wolfgang Fleischhacker; Alex Hofer; Christian Jagsch; Walter Pirker; Georg Psota; Hans Rittmannsberger; Klaus Seppi
Journal:  Neuropsychiatr       Date:  2016-08-31

2.  An experimental model of tardive dyskinesia.

Authors:  H L Klawans; R Rubovits
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

3.  Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding.

Authors:  U Andersson; S A Eckernäs; P Hartvig; J Ulin; B Långström; J E Häggström
Journal:  J Neural Transm Gen Sect       Date:  1990

4.  [Deanol in tardive dyskinesia: a double-blind study (author's transl)].

Authors:  S Bockenheimer; G Lucius
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1976-09-17

5.  Effect of cholinergic and anticholinergic agents on tardive dyskinesia.

Authors:  H L Klawans; R Rubovits
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-08       Impact factor: 10.154

6.  Effects of cholinergic and anticholinergic drugs on ketamine-induced linguopharyngeal motor activity.

Authors:  L A Marco; R S Joshi; C Brown; L D Aldes; R B Chronister
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Pharmacological characterization of tardive dyskinesia.

Authors:  D E Casey; D Denney
Journal:  Psychopharmacology (Berl)       Date:  1977-08-31       Impact factor: 4.530

8.  Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.

Authors:  Jungjin Kim; Eric Macmaster; Thomas L Schwartz
Journal:  Drugs Context       Date:  2014-04-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.